Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED) …
…, B Conrad, S Körner, C Windemuth-Kieselbach… - The Lancet, 2020 - thelancet.com
Background Nivolumab and ipilimumab, alone or in combination, are widely used
immunotherapeutic treatment options for patients with advanced—ie, unresectable or metastatic—…
immunotherapeutic treatment options for patients with advanced—ie, unresectable or metastatic—…
Co-morbidity of adult attention-deficit/hyperactivity disorder with focus on personality traits and related disorders in a tertiary referral center
…, A Dempfle, M Heine, C Windemuth-Kieselbach… - European archives of …, 2007 - Springer
Objective The prevalence and consequences of co-morbid axis-I and axis-II disorders as
well as personality traits were examined in a large cohort of adult attention-deficit/hyperactivity …
well as personality traits were examined in a large cohort of adult attention-deficit/hyperactivity …
[HTML][HTML] The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on …
…, C Jackisch, HJ Lück, C Windemuth-Kieselbach… - Annals of oncology, 2013 - Elsevier
Background Compliance and persistence are often overlooked in adjuvant breast cancer
treatment. Patients and methods PACT was a prospective, multicenter, randomized, open, …
treatment. Patients and methods PACT was a prospective, multicenter, randomized, open, …
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final …
…, B Conrad, S Körner, C Windemuth-Kieselbach… - The Lancet, 2022 - thelancet.com
Background The IMMUNED trial previously showed significant improvements in recurrence-free
survival for adjuvant nivolumab plus ipilimumab as well as for adjuvant nivolumab alone …
survival for adjuvant nivolumab plus ipilimumab as well as for adjuvant nivolumab alone …
[HTML][HTML] Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns—Results of a non-interventional study of …
…, J Maurer, P Wolff, C Windemuth-Kieselbach… - European Journal of …, 2018 - Elsevier
Background Advanced cutaneous squamous cell carcinoma (aSCC) is an area of unmet
medical need and no treatment standards are established. Recently, an anti-PD-1 inhibitor …
medical need and no treatment standards are established. Recently, an anti-PD-1 inhibitor …
A first prospective population-based analysis investigating the actual practice of melanoma diagnosis, treatment and follow-up
E Livingstone, C Windemuth-Kieselbach… - European journal of …, 2011 - Elsevier
Aim of the study: To describe the current management of patients diagnosed with cutaneous
melanoma and melanoma in situ in Germany and assess for adherence with the existing …
melanoma and melanoma in situ in Germany and assess for adherence with the existing …
Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC): A randomized, multicenter DeCOG/ADO study.
…, P Mohr, F Kiecker, M Kaatz, C Windemuth-Kieselbach… - 2018 - ascopubs.org
9527 Background: Merkel cell carcinoma (MCC) is a rare, immunogenic, and highly aggressive
skin cancer. Almost 40% of patients with completely resected MCC will relapse within the …
skin cancer. Almost 40% of patients with completely resected MCC will relapse within the …
[HTML][HTML] Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: Safety and tolerability results from the …
…, D Trebing, K Stelter, C Windemuth-Kieselbach… - European Journal of …, 2021 - Elsevier
Background Combination of immune checkpoint inhibitors and mitogen-activated protein
kinase (MAPK) pathway inhibitors (MAPKi) has been proposed to enhance the durability of anti-…
kinase (MAPK) pathway inhibitors (MAPKi) has been proposed to enhance the durability of anti-…
Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer
…, K Smetanay, C Windemuth-Kieselbach… - Anti-cancer …, 2014 - journals.lww.com
Many patients with metastatic breast cancer (MBC) have been treated previously with taxanes
and/or anthracyclines, which renders reinduction of anthracyclines in the palliative setting …
and/or anthracyclines, which renders reinduction of anthracyclines in the palliative setting …
A gene–environment investigation on personality traits in two independent clinical sets of adult patients with personality disorder and attention deficit/hyperactive …
…, A Dempfle, M Heine, C Windemuth-Kieselbach… - European archives of …, 2010 - Springer
While an interactive effect of genes with adverse life events is increasingly appreciated in
current concepts of depression etiology, no data are presently available on interactions …
current concepts of depression etiology, no data are presently available on interactions …